IMMUNOLOGY

Detailed explanation-1: -Cetuximab (brand name Erbitux) is a monoclonal antibody used in the treatment of metastatic colorectal cancer (mCRC) and cancer of the head and neck. Cetuximab is an epidermal growth factor receptor (EGFR) antagonist, which works by blocking the growth of cancer cells.

Detailed explanation-2: -Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer.

Detailed explanation-3: -Cetuximab has the ability to reverse resistance to irinotecan. Studies in which cetuximab was combined with irinotecan in the treatment of colorectal cancer found improvements in response rates and progression-free survival but not in overall survival.

Detailed explanation-4: -Cetuximab (Erbitux) and panitumumab (Vectibix) are other monoclonal antibodies. These drugs slow cancer growth by targeting a protein found on the surface of some cells called the epidermal growth factor receptor (EGFR). EGFR plays a role in regulating cell growth and is present in about 75% of colon cancers.